Table 1.
Baseline characteristics of study participants based on post-vaccination adverse event status. Data are presented as means with standard deviation or median with interquartile range as appropriate. Proportions are expressed both as numbers and percentages. A p-value less than 0.05 was considered statistically significant. BMI, body mass index; ACE-inhibitors, Angiotensin-converting enzyme-inhibitors; COVID-19, Coronavirus disease; NS, non-significant.
| Total Population (N = 383) | Asymptomatic Group (N = 214) |
Symptomatic Group (N = 169) | p-Value | |
|---|---|---|---|---|
| Age, (mean ± SD) | 46.5 ± 12 | 47.6 ± 12 | 45.3 ± 12 | NS |
| Female, (N, %) | 303 (76.7) | 159 (74.3) | 139 (82.2) | NS |
| BMI, (mean ± SD) | 27.6 ± 6 | 28.1 ± 7 | 26.9 ± 5 | NS |
| Smoking, (N, %) | 123 (34.7) | 73 (37.2) | 50 (31.8) | NS |
| Flu vaccination, (N, %) | 67 (17.6) | 37 (17.5) | 30 (17.9) | NS |
| Hypertension, (N, %) | 95 (26) | 55 (28.2) | 40 (23.7) | NS |
| Diabetes, (N, %) | 22 (6) | 14 (7.2) | 8 (4.7) | NS |
| Hypothyreosis, (N, %) | 25 (6.9) | 15 (7.7) | 10 (5.9) | NS |
| Autoimmune disease, (N, %) | 20 (5.5) | 10 (5.2) | 10 (5.9) | NS |
| Allergy, (N, %) | 96 (26.2) | 36 (18.3) | 60 (35.5) | <0.001 |
| ACE inhibitors, (N, %) | 63 (17.4) | 34 (17.6) | 29 (17.2) | NS |
| Beta blockers, (N, %) | 60 (16.5) | 30 (15.5) | 30 (17.8) | NS |
| Calcium channel blocker, (N, %) | 25 (6.9) | 9 (4.7) | 16 (9.5) | NS |
| Prior COVID-19 infection, (N, %) | 85 (23.2) | 47 (24) | 38 (22.5) | NS |